PMID- 22783357
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20211021
IS  - 2092-9129 (Electronic)
IS  - 1738-7949 (Print)
IS  - 1738-7949 (Linking)
VI  - 47
IP  - 2
DP  - 2012 Jun
TI  - The effectiveness of tacrolimus and minidose methotrexate in the prevention of 
      acute graft-versus-host disease following allogeneic hematopoietic stem cell 
      transplantation in children: a single-center study in Korea.
PG  - 113-8
LID - 10.5045/kjh.2012.47.2.113 [doi]
AB  - BACKGROUND: Knowledge of the roles of tacrolimus and minidose methotrexate (MTX) 
      in the prevention of acute graft-versus-host disease (aGVHD) in pediatric 
      allogeneic hematopoietic stem cell transplantation (HSCT) is limited. We 
      retrospectively evaluated the engraftment status, incidence of aGVHD and chronic 
      GVHD (cGVHD), and toxicities of tacrolimus and minidose MTX in aGVHD prophylaxis 
      in children undergoing allogeneic HSCT. METHODS: Seventeen children, who 
      underwent allogeneic HSCT and received tacrolimus and minidose MTX as GVHD 
      prophylaxis from March 2003 to February 2011, were reviewed retrospectively. All 
      the patients received tacrolimus since the day before transplantation at a dose 
      of 0.03 mg/kg/day and MTX at a dose of 5 mg/m(2) on days 1, 3, 6, and 11. 
      RESULTS: Of the 17 patients, 9 received human leukocyte antigen (HLA)-matched 
      related donor transplants, and 8 received HLA-matched, or partially mismatched 
      unrelated donor transplants. The median time for follow-up was 55 months. The 
      incidence of aGVHD in the related and unrelated donor groups was 22.2% and 42.9%, 
      respectively. cGVHD was not observed. To maintain therapeutic blood levels of 
      tacrolimus, the younger group (<8 years of age) required an increased mean dose 
      compared to the older group (>/=8 years) (P=0.0075). The adverse events commonly 
      associated with tacrolimus included hypomagnesemia (88%), nephrotoxicity (23%), 
      and hyperglycemia (23%). CONCLUSION: Tacrolimus and minidose MTX were well 
      tolerated and effective in GVHD prophylaxis in pediatric patients undergoing 
      allogeneic HSCT. Children <8 years of age undergoing HSCT required increased 
      doses of tacrolimus to achieve therapeutic levels.
FAU - Park, Seong Shik
AU  - Park SS
AD  - Department of Pediatrics, Pusan National University College of Medicine, Busan, 
      Korea.
FAU - Jun, So Eun
AU  - Jun SE
FAU - Lim, Young Tak
AU  - Lim YT
LA  - eng
PT  - Journal Article
DEP - 20120626
PL  - Korea (South)
TA  - Korean J Hematol
JT  - The Korean journal of hematology
JID - 101486388
PMC - PMC3389059
OTO - NOTNLM
OT  - Acute graft-versus-host disease
OT  - Allogeneic hematopoietic stem cell transplantation
OT  - Children
OT  - Methotrexate
OT  - Tacrolimus
EDAT- 2012/07/12 06:00
MHDA- 2012/07/12 06:01
PMCR- 2012/06/01
CRDT- 2012/07/12 06:00
PHST- 2012/02/06 00:00 [received]
PHST- 2012/03/19 00:00 [revised]
PHST- 2012/05/16 00:00 [accepted]
PHST- 2012/07/12 06:00 [entrez]
PHST- 2012/07/12 06:00 [pubmed]
PHST- 2012/07/12 06:01 [medline]
PHST- 2012/06/01 00:00 [pmc-release]
AID - 10.5045/kjh.2012.47.2.113 [doi]
PST - ppublish
SO  - Korean J Hematol. 2012 Jun;47(2):113-8. doi: 10.5045/kjh.2012.47.2.113. Epub 2012 
      Jun 26.